<DOC>
	<DOCNO>NCT02281383</DOCNO>
	<brief_summary>This phase II study . This mean BCG therapy already find safe human . The investigator want see use treatment work well .</brief_summary>
	<brief_title>Evaluate Response 2 Induction Courses ( 12 Intravesical Instillations ) Bacillus Calmette-Guérin ( BCG ) High Risk Superficial Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>Patients must high risk nonmuscle invasive urothelial bladder carcinoma ( Tis , TaHG , T1 ) pathologically confirm Memorial Sloan Kettering Department Pathology document history TaHG T1 nonmuscle invasive urothelial bladder tumor . 18 year old All visible papillary lesion must macroscopically resect within 60 day treatment initiation . Absence urothelial carcinoma involve upper urinary tract ( documented radiological image biopsy ) preferably within 12 month start treatment . Should image biopsy perform outside window physician discretion rescan/biopsy . Patients receive single dose mitomycin C follow stag TUR . Currently treat schedule radiation treatment bladder cancer study . Treatment intravesical BCG chemotherapy patient 's current &lt; T2 tumor 12 month prior current diagnosis . Currently treat schedule treatment systemic intravesical chemotherapeutic agent study . Currently treat treat last 12 month investigational drug high risk superficial bladder cancer . Previous muscleinvasive ( i.e. , stage T2 high ) transitional cell carcinoma bladder . Currently treat metastatic transitional cell carcinoma . Scheduled surgery bladder cancer study . Presence clinically significant infection congenital acquired immunodeficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bacillus Calmette-Guérin ( BCG )</keyword>
	<keyword>14-174</keyword>
</DOC>